Search results
Results from the WOW.Com Content Network
Titan's principal asset is Probuphine, [5] [6] a slow-release implant formulation of buprenorphine [7] for the treatment of opioid addiction or chronic pain. FDA Approval was granted on 26 May 2016. [8] It was licensed to Braeburn Pharmaceuticals for marketing and commercialization. [6]
Carbonate derivatives of 14β-hydroxycodeine "viz., 14β-hydroxy-6-O-(methoxycarbonyl)codeine, 6-O-methoxycarbonyl-14β-(methoxycarbonyloxy)codeine, and 14β-acetoxy-6-O-methoxy-carbonylcodeine, potential substrates for ring C modification in morphinane (sic) alkaloids, were synthesized for the first time."
It was the first time that the FDA had "taken steps to remove a currently marketed opioid pain medication from sale due to the public health consequences of abuse." [46] In 2021, New York Attorney General Letitia James filed a lawsuit against Endo and several other opioid manufacturers for their alleged contribution to the opioid epidemic in ...
The law (TN Code 53-11-311) that prevents nurse practitioners (NPs) or physician assistants (PAs) from prescribing more than 16 milligrams of buprenorphine-naloxone daily (despite standard dosing ...
Global consulting firm McKinsey & Company agreed Friday to pay $650 million to resolve criminal and civil investigations into the advice it provided to opioids manufacturer Purdue Pharma. As part ...
This is the list of Schedule II controlled substances in the United States as defined by the Controlled Substances Act. [1] The following findings are required for substances to be placed in this schedule: [ 2 ]
McKinsey & Co has agreed to pay $650 million to resolve a US Department of Justice investigation into the consulting firm’s work advising opioid manufacturer OxyContin maker Purdue Pharma on how ...
A US Drug Enforcement Administration (DEA) database tracking every opioid pill sold in the United States from 2006 through 2012 was made public in 2019. The database "attributed the vast majority of the 76 billion opioid pills produced and shipped from 2006 through 2012 to three companies", one of which was SpecGx, a subsidiary of Mallinckrodt.